Abstract: Objective: To observe the clinical effect and safety of 0.5% Timolol Maleate Eye Drops as a topical drug in the treatment of superficial infantile hemangioma (IH) of the maxillofacial region. Methods: A total of 40 infants(age from 5 weeks to 24 weeks) with superficial hemangiomas of the jaw (without ulceration and apart from the oral mucosa) were randomly assigned to the control group and the experience group. The control group was treated with oral administration of propranolol (1.0 mg/kg, 1 time/day), while the experience group was locally application of 0.5% Timolol Maleate Eye Drops in the hemangioma region. The effect was assessed by comparison of changes of lesion areas at 0, 1, 2, 4, 8, 12, 16, 20 and 24 weeks, and pictures taken at 0, 12, and 24 weeks. The safety assessment was weekly measured by heart rate and blood pressure. Results: In 20-24 weeks after the treatment, we found that there were significant differences in size and color (P<0.05) between the two groups. As to the clinical effect and adverse reactions, no significant difference were found. Conclusion: Local use of 0.5% Timolol Maleate Eye Drops as the treatment of choice in maxillofacial IH seems a safe and effective option.

Key words: 0.5% Timolol Maleate, infantile hemangioma (IH), maxillofacial region, propranolol

摘要： 目的：观察0.5%马来酸噻吗洛尔滴眼液作为药物局部使用，治疗颌面部表浅型婴幼儿血管瘤（infantile hemangioma, IH）的临床疗效及安全性。方法：选择40例5~24周患有颌面部表浅型婴幼儿血管瘤（无溃疡、不接近口腔黏膜）的婴幼儿，随机分为对照组和治疗组。对照组采用口服普萘洛尔（1.0 mg/kg，1次/日）治疗，治疗组用 0.5%马来酸噻吗洛尔滴眼液局部外涂病变区域。对比治疗后第1、2、4、 8、12、16、20及24周时的病变面积，以及第0、12和24周的照片，评估疗效。安全评估则通过测量心率、血压来评价。结果：在治疗后20~24周时，我们发现局部使用0.5%马来酸噻吗洛尔滴眼液治疗的患者，在体积、颜色的改变上更优于口服普萘洛尔治疗（P<0.05），但两组的临床疗效及不良反应无明显差异。结论：对于那些没有溃疡且没有接近黏膜的颌面部表浅型IH来说，局部使用0.5%马来酸噻吗洛尔滴眼液是一种安全有效的选择。

关键词: 0.5%马来酸噻吗洛尔, 婴幼儿血管瘤, 颌面部, 普萘洛尔

CLC Number: 

• R782.4